The NFL’s Campaign Against Breast Cancer Is a Total Scam

 

The NFL's Campaign Against Breast Cancer Is a Total Scam“Have you noticed that during the month of October, the NFL suddenly becomes intensely concerned with making sure you’re aware of breast cancer? Pink jerseys! Huge Ass Pink Ribbons at midfield! Pink motherfucking cleats! Fans interested in aware-ing on their own can even click on over to the NFL’s store and purchase ugly pink crap of their own under the assumption that their good intentions will actually contribute to the fight against cancer. Well, I hate to burst your Pepto Bismo Pink bubble, wearers of dangly earrings that contain both ribbons and tiny footballs, but you’ve been had — the NFL’s Breast Cancer Awareness Month campaign does raise itsy bitsy amounts of money for the fight against cancer, but the amount of money it raises pales in comparison to the amount of money it raises for billionaire NFL owners.

The NFL claims that its pink philanthropy efforts “support the fight against breast cancer” by “promoting awareness” and providing funds to the American Cancer Society. But what they’re mostly promoting is, uh, buying NFL gear, the profits from which are overwhelmingly pocketed by the NFL.

According to Business Insider, the NFL’s October Breast Cancer Awareness Month fundraising effort is multi-pronged. There’s the on-field onslaught of pink (AWARENESS), the off-field auction of autographed or otherwise noteworthy NFL paraphernalia (MONEY FOR THE CURE!), and the part of the NFL store that entices shoppers to purchase officially licensed NFL breast cancer gear, a portion of which goes to FINDING A CURE. According to the League, 100% of the proceeds from the specialty auction go to the American Cancer Society, but the total percentage of purchases of officially licensed gear that actually goes to FINDING A CURE is actually kind of pathetic — 5%. If you want to look at this cynically, in a way, the on-field wearin’ o’ the pink serves as an ad to direct consumers to purchase pink fan items.

BUT WAIT, you might say, AT LEAST THEY’RE DOING SOMETHING. And 5% is still something! Well, kind of. As BI pointed out, if NFL products are sold at a 100% markup and only 5% of sale proceeds go to the American Cancer Society, then the NFL is pocketing 90% of sales of Breast Cancer Awareness products, many of which would not be purchased if they didn’t come with a promise that consumers were “helping.” And, more perspective: while the American Cancer Society isn’t, say, Komen, they still don’t use 100% of the money they receive to “fight” breast cancer. Only 70% of donations taken in by the organization go toward cancer research. So, if you spend $10 on pink stink from the NFL, only about 35 cents is going to finding a cure for breast cancer. And $4.50 goes right back to the NFL, where I like to imagine that it’s spent on gas for a Lake Minnetonka pleasure cruise. For the cure.

But what about awareness?! Surely the NFL is helping keep people aware and alert and vigilant that at any moment, breast cancer could be lurking around a corner in a dark alley waiting with a hot pink switchblade to steal your purse and boobs. The thing about awareness is that it’s all but impossible to quantify — and everyone knows about breast cancer. If you asked 100 people if they’re aware that breast cancer is a thing and that it’s almost impossible to predict and most often affects women, I’d bet that most of them would nod before slowly backing away from you. Breast cancer awareness is so ubiquitous that if deadly diseases attended the same high school, breast cancer would probably be voted prom queen. The “awareness” that comes from the NFL’s sales of pink branded items doesn’t justify the extent to which the league is taking advantage of consumers’ good intentions to pad their wallets. Even if no NFL player ever touched another pink thing again, Americans would go right on being aware of the disease. Unless the Buffalo Jills or New Orleans Saintsations cheerleaders are holding up signs that show women how to give themselves breast self-exams or tickets come with 5 page printouts of places low income women can obtain breast health screening for low or no cost, the type of awareness the NFL is providing is useless, vague garbage.

Since the program’s inception four years ago, the NFL has raised $3 million for breast cancer. In 2009, the League made $8.5 billion. Last year, they made $9.5 billion. Commissioner Roger Goodell has set a revenue goal of $25 billion per year by the year 2027. A million per year out of between $8.5 and $9.5 billion in revenues? Pardon me while I don’t slobber all over the NFL’s pink-drenched marketing campaign.

Want to cure breast cancer? Give directly to an organization that cures breast cancer, or to an advocacy group that seeks actual cures, not marketing and corporate profits. Besides, wearing those horrid pink NFL breast cancer rain boots actually causes cancer. Of the eyes.”

http://jezebel.com/5950971/the-nfls-campaign-against-breast-cancer-is-a-total-scam

Is the pink ribbon campaign a scam?

“The pink ribbon has become synonymous with solidarity for women who battle breast cancer. After all, a diagnosis of breast cancer changes the life of the diagnosed and the lives of all those involved — many times for the worse.

But, did you ever stop to think about what the pink ribbon campaign is all about? Is it really meant to bring “awareness” to breast cancer? Hasn’t everyone heard of breast cancer? Some have questioned the motives of those who stand behind those pretty pink ribbons.

Some have suggested that Breast Cancer Awareness month can be seen as a push for women to be corralled into the mammography suite so they can await their breast cancer diagnosis when the mammography is complete.

The science behind mammography is clear. Mammography does more harm than good.

Yes, the concept seems harsh. After all, most people who wear pink ribbons are innocent. They just go along with the rest. It’s a chance to show that they support the cause, whatever that is.

The pink ribbon campaign, however, is not completely innocent. Take for example this questionable involvement in the pink ribbon campaign. In October 2010, KFC filled and sold the “Bucket for the Cure,” donating 50 cents to breast cancer for each bucket sold. If KFC had a real interest for preventing breast cancer or for finding its cure, wouldn’t they close their doors forever? After all, the Physicians Committee for Responsible Medicine (PCRM) sued KFC for not disclosing to its customers that the chicken sold at KFC contained a dangerous carcinogen. “KFC should post warnings because its aggressively marketed new product harbors a chemical that increases the risk of breast cancer, prostate cancer, and other forms of this lethal disease,” commented Dr. Neal Barnard, of PCRM.

While some participants in the pink ribbon campaign do send raised funds to breast cancer charities, such as Komen for the Cure, others do not follow through with contributions. The Better Business Bureau has issued warnings to consumers regarding this shell game.

Pink Ribbons have hope. On the other hand, the entire breast cancer awareness initiative would be worthwhile if we continued to raise money to advertise the information that we already have about breast cancer prevention: diet, exercise, stress management prevent breast cancer. Why is it that people do not know that eating a low-fat whole plant foods diet is the single most important thing you can do to prevent breast cancer? Why don’t breast cancer organizations teach what we already know instead of continuing to look for a cure that comes in an expensive pill, treatment, or surgery?

Who’s benefiting here, anyway?”

Marijuana: A cure for breast cancer

“Cannabis, or rather marijuana, has been known as an illegal drug that is used primarily to get “high” and has no other value. This is what many people have thought of marijuana for at least the last 75 years.

Over the years, numerous research studies have been conducted on cannabis and there were discussions about its medicinal benefits for cancer treatment; however, because this is an illegal drug, much of the research hasn’t been known to the average citizen.

Within the last 10-15 years, the interest in cannabis as a possible cure for cancer has increased substantially. In addition, there has been an increase in citizens demanding the ability to use medicinal cannabis as a treatment for their disease or illness.

These recent studies have shown that cannabis may be a cure for cancer.  One study
conducted in 2007 by the California Pacific Medical Center in San Francisco, CA determined that a compound in cannabis called “Cannabidiol” was effective at inhibiting aggressive breast cancers. It was discovered that a certain “key gene caused breast cancer to spread and that cannabidiol could inhibit that aggressive gene by stopping the spread of the tumor cells”.  This study was published in the Washington Post and Science Daily
as well.

Unfortunately, cannabis is a schedule 1 drug which means that additional research and FDA approval would be required for cannabis to be used for the treatment of cancer.  It would require the removal of cannabis as a schedule 1 drug.

There is information that may suggest the U.S. Government and the Drug Enforcement Agency (DEA) may have already known about the benefits of cannabis to treat cancer. The National Cancer Institute published a study in 1974. Due to federal law, no further studies were conducted until the 1990’s. All research conducted since then has been via test tube and animal studies.

In an October 2003 review on test tube and animal research indicated that cannabinoids inhibit tumors of the lung, uterus, skin, breast, prostate, and brain. Cannabis is also known to provide nausea relief to cancer patients and to increase appetite.

Medicinal cannabis may be the cure for cancer. Additional research is needed; however, it may require reclassifying cannabis in order to obtain government approval.”

http://www.examiner.com/article/marijuana-a-cure-for-breast-cancer

Marijuana compound could help fight breast cancer – ABC News

“There may be a new weapon in the fight against aggressive forms of breast cancer in the future, and it comes from an unlikely source: Marijuana. Researchers at California Pacific Medical Center in San Francisco believe a compound in marijuana may help.

The research funded by the California Breast Cancer Research Program builds on more than a decade of studies involving the genes responsible for the spread of cancer. Now scientists have found at the cellular level, a compound in cannabis inhibits the gene that controls the spread of cancer.

“The problem is not the cancer itself, the problem is the spread of the cancer,” said cancer researcher Yvez Desprez, Ph.D.

Cancer researcher Pierre Desprez points to the gene ID-1 as the trigger.

“When this type of gene is expressed, the cells basically go crazy and they’re very aggressive and they metastasize everywhere in the body,” said Desprez.

“We could expect that if we create really effective inhibitors against it, we could potentially treat many types of aggressive cancers,” said cancer researcher Sean McAllister, Ph.D.

Their research in breast cancer cell lines focused on using a non-toxic compound in cannabis to target the ID-1 gene.

“What we found was cannabidiol is a particularly good inhibitor of this gene that’s responsible for the ability of cancer cells to become very aggressive,” said McAllister.”

http://abclocal.go.com/kgo/story?section=news/health&id=5771385

Scientists believe marijuana compound could fight cancer

“Scientists in California believe they may have discovered a compound in marijuana that can reduce the aggressiveness of some forms of cancer.

The San Francisco Gate reports on the data that has been years in the making. While marijuana has been shown to help reduce nausea and pain in cancer patients, scientists believe that a compound in marijuana has the ability to “turn off” the activity of a gene responsible for metastasis in breast and other types of cancers.

The research team is working out of San Francisco’s California Pacific Medical Center Research Institute and have been working for years on the study. The compound they’re focused on, called cannabidiol, does not produce the psychotropic high associated with marijuana.

Last year, the team published a small study showing the positive effects of cannabidiol on mice. New data is about to be released that expands upon the previous results that the researchers hope will help propel the study even further.

“The preclinical trial data is very strong, and there’s no toxicity. There’s really a lot of research to move ahead with and to get people excited,” said Sean McAllister, who is working alongside scientist Pierre Desprez in the study.

Desprez and McAllister believe that their merging of separate areas of study was serendipitous.

Desprez had been studying the protein ID-1, which he found to play an important role in how cancer could spread. McAllister, on the other hand, was focused on studying anabolic steroids in drug abuse. He soon became focused on with the role non-psychotropic cannabidiol, or CBD, interacts with cancer.

McAllister, after hearing an internal seminar from Desprez on his studies of ID-1, came up with the question “How effective would cannabidiol be on targeting metastatic cancer cells?”

The two then teamed up, with Desprez armed with ID-1 cancer-causing protein, and McAllister with CBD, his cancer-fighting compound.

For their experimentation, the doctors exposed ID-1 to CBD in a petri dish. In a shocking result, the ID-1, the cancer-causing protein, reverted to a normal state and stopped acting “crazy.”

“We thought we did the experiment the wrong way,” McAllister said of the overwhelming results.

However, their results proved to be consisted.

“I told Sean, ‘Maybe your drug is working through my gene,’ ” Desprez said.

What the researchers have discovered thus far in their research is that CBD turns off the overexpression of ID-1, which prevents it from traveling to foreign tissues. Thus, the metastasization – cancer’s fatal ability – is blocked.

In the wake of their positive results, the doctors were forced to emphasize that the CBD will only work in the presence of high levels of ID-1 and these do not include all cancerous tumors but, rather, aggressive, metastatic cells. High levels have been found in leukemia, colorectal, pancreatic, lung, ovarian, brain and other cancers.”
Read more: http://www.irishcentral.com/news/Scientists-believe-marijuana-compound-could-fight-cancer-170689736.html#ixzz29rQbc2oS

Can Cannabidiol (CBD) Fight Metastatic Cancer? According to the latest research the answer is yes. Important news for Medical Marijuana, Inc.’s new line of high concentrate CBD health and wellness products.

“(OTC: MJNA), a leading hemp industry innovator, is pleased to report on a September 18 San Francisco Chronicle Article, “Pot compound seen as tool against cancer.” The article states that scientists at California Pacific Medical Center who have been researching marijuana’s compounds for the 20 years have found that Cannabidiol, or CBD, has the ability to “turn off” the DNA that causes “breast and other types of cancers” to metastasize. CBD is the second-most abundant cannabinoid within marijuana, but does not cause the psychotropic high of THC.

As stated in the article: “We started by researching breast cancer,” said scientist Pierre Desprez. “But now we’ve found that Cannabidiol works with many kinds of aggressive cancers–brain, prostate–any kind in which these high levels of ID-1 are present.” Desprez said he is hopeful clinical trials will begin immediately. He currently has grant funding through the National Institutes of Health, Susan G. Komen for the Cure, the U.S. Department of Defense and the California Breast Cancer Research Program.

As previously announced in the MJNA press release dated September 5, MJNA portfolio company, Red Dice Holdings, recently launched its Hemp-based high concentrate CBD health and wellness products, Dixie X, for over-the-counter sales. These Cannabidiol products represent the highest strength of CBD products on the market today, and this same concentrate will soon be used to launch the CanChew Biotechnologies line of CBD-enriched chewing gum. Click here for recent production news from PhytoSphere. Dixie X can currently be purchased in over 100 retail locations in Colorado, Arizona and New Mexico as well as on-line by anyone living in the U.S.

In short, MJNA and its portfolio company, PhytoSphere Systems, currently produces non-THC, high quality CBD enriched Hemp oil that according to this story, may fight the most aggressive forms of cancers we know of today.

Studies, such as those in this article and at Project CBD, have continually shown that these non-psychoactive CBD wellness products provide powerful relief for pain and anxiety sufferers, but without the euphoric effects provided by THC. The CBD health and wellness industry is estimated by MJNA to be a $5 billion market.”

http://www.cnbc.com/id/49117540/Can_Cannabidiol_CBD_Fight_Metastatic_Cancer_According_to_the_latest_research_the_answer_is_yes_Important_news_for_Medical_Marijuana_Inc_s_new_line_of_high_concentrate_CBD_health_and_wellness_products

NBC News Reports that Cannabidiol (CBD) “Turns Off” the Cancer Gene Involved in Metastasis Findings by Scientists at California Pacific Medical Center gives Scientific Support for Cannabis Science

“Cannabis Science (CBIS), a pioneering U.S. Biotech Company developing pharmaceutical products for global public health challenges, reports on a recent press release by the San Francisco NBC news, with new studies by Scientists at California Pacific Medical Center, which have shown that cannabidiol, (CBD -1.18%, news), has the ability to “turn off” a gene that causes breast and other types of cancers to metastasize, according to the San Francisco Chronicle newspaper.

NBC News reports, “The drug “has been shown to reduce pain and nausea” in cancer patients. AIDS patients also use cannabis to eat, sleep and otherwise be more functional. Turns out that cannabidiol has none of the psychotropic effects of marijuana as a whole. The researchers hope to move to clinical trials on humans soon to test the cannabidiol inhibition of metastasis, reported in the San Francisco Chronicle. “What they found is that the cannabinoid turns off the overexpression of ID-1, which makes the cells lose their ability to travel to distant tissues. In other words, it keeps the cells more local and blocks their ability to metastasize. (spread to a new location) The researchers stressed cannabidiol works only on cancer cells that have these high levels of ID-1 and these do not include all cancerous tumors but, rather, aggressive, metastatic cells. But they’ve found such high levels in leukemia, colorectal, pancreatic, lung, ovarian, brain and other cancers.””

http://money.msn.com/business-news/article.aspx?feed=BW&date=20120920&id=15582334

[The endocannabinoid system as a target for the development of new drugs for cancer therapy].

Image result for recenti progressi in medicina

“Studies on the main bioactive components of Cannabis sativa, the cannabinoids, and particularly delta 9-tetrahydrocannabinol (THC), led to the discovery of a new endogenous signalling system that controls several physiological and pathological conditions: the endocannabinoid system. This comprises the cannabinoid receptors, their endogenous agonists–the endocannabinoids–and proteins for endocannabinoid biosynthesis and inactivation.

Recently, evidence has accumulated indicating that stimulation of cannabinoid receptors by either THC or the endocannabinoids influence the intracellular events controlling the proliferation and apoptosis of numerous types of cancer cells, thereby leading to anti-tumour effects both in vitro and in vivo.

This evidence is reviewed here and suggests that future anti-cancer therapy might be developed from our knowledge of how the endocannabinoid system controls the growth and metastasis of malignant cells.”

http://www.ncbi.nlm.nih.gov/pubmed/12723496

Endocannabinoid system modulation in cancer biology and therapy.

Cover image

“The discovery of the endocannabinoid system and the recognition of its potential impact in a plethora of pathological conditions, led to the development of therapeutic agents related to either the stimulation or antagonism of CB1 and CB2 cannabinoid receptors, the majority of which are actually tested in preclinical studies for the pharmacotherapy of several diseases. Endocannabinoid-related agents have been reported to affect multiple signaling pathways and biological processes involved in the development of cancer, displaying an interesting anti-proliferative, pro-apoptotic, anti-angiogenic and anti-metastatic activity both in vitro and in vivo in several models of cancer. Emerging evidence suggests that agonists of cannabinoid receptors, which share the useful property to discern between tumor cells and their non-transformed counterparts, could represent novel tumor-selective tools to treat cancer in addition to their already exploited use as palliative drugs to treat chemotherapy-induced nausea, pain and anorexia/weight loss in cancer patients. The aim of this review is to evidence and update the recent emerging knowledge about the role of the endocannabinoid system in cancer biology and the potentiality of its modulation in cancer therapy.”  http://www.ncbi.nlm.nih.gov/pubmed/19559362

http://www.sciencedirect.com/science/article/pii/S1043661809000863

Changes in the Endocannabinoid System May Give Insight into new and Effective Treatments for Cancer

Logo of nihpa

“The endocannabinoid system comprises specific cannabinoid receptors such as Cb1 and Cb2, the endogenous ligands (anandamide and 2-arachidonyl glycerol among others) and the proteins responsible for their synthesis and degradation. This system has become the focus of research in recent years because of its potential therapeutic value several disease states. The following review describes our current knowledge of the changes that occur in the endocannabinoid system during carcinogenesis and then focuses on the effects of anandamide on various aspects of the carcinogenic process such as growth, migration, and angiogenesis in tumors from various origins.

Marijuana and its derivatives have been used in medicine for centuries, however, it was not until the isolation of the psychoactive component of Cannabis sativa (Δ9-tetrahydrocannabinol; Δ9-THC) and the subsequent discovery of the endogenous cannabinoid signaling system that research into the therapeutic value of this system reemerged. Ongoing research is determining that regulation of the endocannabinoid system may be effective in the treatment of pain (Calignano et al., 1998; Manzanares et al., 1999), glaucoma (Voth and Schwartz, 1997), and neurodegenerative disorders such as Parkinson’s disease (Piomelli et al., 2000) and multiple sclerosis (Baker et al., 2000). In addition, cannabinoids might be effective anti-tumoral agents because of their ability to inhibit the growth of various types of cancer cell lines in culture (De Petrocellis et al., 1998; Ruiz et al., 1999; Sanchez et al., 1998, 2001) and in laboratory animals (Galve-Roperh et al., 2000).

In conclusion, the endocannabinoid system exerts a myriad of effects on tumor cell growth, progression, angiogenesis, and migration. With a notable few exceptions, targeting the endocannabinoid system with agents that activate cannabinoid receptors or increase the endogenous levels of AEA may prove to have therapeutic benefit in the treatment of various cancers. Further studies into the downstream consequences of AEA treatment are required and may illuminate other potential therapeutic targets.”

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2791688/